ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Body Mass Index Outperforms Triglyceride-Glucose Index in Predicting MAFLD in Type 2 Diabetes: A Cross-Sectional Mediation and Interaction Analysis.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The interplay between body mass index (BMI) and triglyceride-glucose (TyG) has yet to be systematically investigated on metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus (T2DM). This knowledge gap regarding the specific nature of their combined effects limits our ability to develop precise risk stratification algorithms and targeted intervention strategies. Purpose: This study aimed to investigate the independent and synergistic roles of BMI and TyG in MAFLD development among T2DM patients. Methods: A cross-sectional study was conducted among 816 T2DM patients recruited from the Affiliated Hospital of Nanjing University of Chinese Medicine. MAFLD was diagnosed via Fibroscan. Dose-response relationships were assessed using restricted cubic splines (RCS). Multiplicative and additive interactions were evaluated using logistic regression models. Causal mediation analysis quantified the proportion of the BMI-MAFLD association mediated by TyG. Predictive performance was compared using receiver operating characteristic (ROC) curves. Results: Among 816 participants, 528 (64.7%) had MAFLD. RCS confirmed linear positive associations of BMI and TyG with MAFLD. Compared to those with BMI <24 kg/m Conclusion: In T2DM, BMI exhibited a stronger association with MAFLD risk than TyG, with TyG accounting for a portion of this association but providing limited incremental improvement in discriminative ability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.